Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$0.32 - $0.62 $392,000 - $759,500
-1,225,000 Reduced 14.89%
7,000,000 $4.34 Million
Q3 2023

Nov 14, 2023

SELL
$0.46 - $0.65 $356,500 - $503,750
-775,000 Reduced 8.61%
8,225,000 $3.95 Million
Q4 2022

Feb 14, 2023

BUY
$1.1 - $2.45 $715,000 - $1.59 Million
650,000 Added 7.78%
9,000,000 $11.2 Million
Q3 2022

Nov 14, 2022

BUY
$1.96 - $3.32 $1.34 Million - $2.27 Million
685,000 Added 8.94%
8,350,000 $17.2 Million
Q2 2022

Aug 15, 2022

BUY
$2.27 - $4.86 $3.46 Million - $7.41 Million
1,525,000 Added 24.84%
7,665,000 $21.2 Million
Q1 2022

May 16, 2022

BUY
$3.69 - $5.65 $883,537 - $1.35 Million
239,441 Added 4.06%
6,140,000 $26.8 Million
Q4 2021

Feb 14, 2022

BUY
$5.37 - $7.07 $1.6 Million - $2.11 Million
298,246 Added 5.32%
5,900,559 $32.6 Million
Q3 2021

Nov 15, 2021

BUY
$5.54 - $7.51 $1.87 Million - $2.53 Million
337,313 Added 6.41%
5,602,313 $34.6 Million
Q2 2021

Aug 16, 2021

BUY
$7.78 - $11.4 $1.17 Million - $1.71 Million
150,288 Added 2.94%
5,265,000 $44.8 Million
Q1 2021

May 17, 2021

BUY
$5.12 - $8.48 $4.22 Million - $7 Million
825,000 Added 19.23%
5,114,712 $40.5 Million
Q4 2020

Feb 16, 2021

BUY
$3.16 - $7.03 $2.02 Million - $4.5 Million
639,712 Added 17.53%
4,289,712 $25 Million
Q2 2020

Aug 14, 2020

BUY
$1.58 - $4.63 $3.4 Million - $9.95 Million
2,150,000 Added 143.33%
3,650,000 $16.8 Million
Q1 2020

May 15, 2020

BUY
$1.44 - $3.02 $1.55 Million - $3.25 Million
1,075,000 Added 252.94%
1,500,000 $2.37 Million
Q3 2019

Nov 14, 2019

BUY
$2.67 - $3.65 $600,750 - $821,250
225,000 Added 112.5%
425,000 $1.25 Million
Q2 2019

Aug 14, 2019

BUY
$2.6 - $4.21 $520,000 - $842,000
200,000 New
200,000 $575,000

Others Institutions Holding AFMD

About Affimed N.V.


  • Ticker AFMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,339,008
  • Market Cap $520M
  • Description
  • Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...
More about AFMD
Track This Portfolio

Track 683 Capital Management, LLC Portfolio

Follow 683 Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of 683 Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on 683 Capital Management, LLC with notifications on news.